Catalyst Event
Eli Lilly and Co (LLY) · Other
From KEDI Global Obesity Care Industry Top 2+ Index (OBCI)
4/16/2026, 12:00:00 AM
Eli Lilly is expected to announce Foundayo's heart safety trial results and the FDA's request for additional data on April 16, 2026. Medium impact is estimated based on the clinical significance of obesity treatments expected.
Korean Translation
2026년 4월 16일 파운다요의 심장 안전성 시험 결과 발표 및 FDA의 추가 데이터 요청이 예상됨. 비만 치료제 임상 데이터의 중요성을 고려하여 중간 수준의 영향이 예상됨.
Related Recent Events
Novo Nordisk A/S (NVO) · Earnings Release
Novo Nordisk is scheduled to release its Q1 2026 earnings report before the market opens on May 6, 2026, with high importance estimated due to potential 10% price impact, expected.
5/6/2026, 12:00:00 AM
Life Time Group Holdings Inc (LTH) · Earnings Release
Life Time Group Holdings is scheduled to report its Q1 2026 financial results. A moderate market reaction is estimated for this standard earnings release scheduled.
5/5/2026, 12:00:00 AM
Eli Lilly and Co (LLY) · Earnings Release
Eli Lilly is scheduled to announce its first-quarter 2026 financial results on April 30, 2026, followed by a conference call. High impact is estimated due to significant market focus on GLP-1 sales growth scheduled.
4/30/2026, 12:00:00 AM
Merck and Co Inc (MRK) · Earnings Release
Merck & Co. is scheduled to release its Q1 2026 earnings on April 30, 2026; impact is estimated as neutral pending the actual report, scheduled.
4/30/2026, 12:00:00 AM
Amgen Inc (AMGN) · Earnings Release
Amgen is expected to report its Q1 2026 financial results after the market closes on April 30, 2026, scheduled. Analysts estimate a Low impact (~1-2%) as a standard scheduled reporting event, scheduled.
4/30/2026, 12:00:00 AM
Astrazeneca PLC (AZN) · Earnings Release
AstraZeneca's Q1 2026 results announcement is scheduled for April 29, 2026 scheduled
4/29/2026, 12:00:00 AM